• 18 OCT 16
    • 0

    HSRAANZ Annual General Meeting and Symposium – Health Services Research – where to from here? A review of the state and potential of HSR in Australia and New Zealand

    Registrations are now open for the Association’s Annual General Meeting and Symposium – Health Services Research – where to from here? on 1 December 2016 at the National Press Club, Canberra. At the event we will launch the preliminary findings of a commissioned report on the state and potential of HSR in Australia and New Zealand. This will be accompanied by short presentations by leading health services researchers describing the impact of their HSR on the Australian and New Zealand healthcare system and population health. Following the report launch and presentations, we will be holding break-out sessions to discuss the potential role and approaches to HSR in Australia and New Zealand in different sectors of the healthcare system (e.g. public hospitals, primary care, aged care, public health).

    Read more →
    • 18 OCT 16
    • 0

    HSRAANZ Members – tell us about your research

    We want to encourage and help HSRAANZ members to publicise their research. You can do this simply, by completing our template. All we require is a 500 word summary for the HSRAANZ Blog, a 100 word summary for the HSRAANZ email newsletter and a 140 character summary for @hsraanz so that we can tweet about the paper and share a link to the blog. You can also post a photo of yourself or your team. For an example of how this can be done take a look at the post below “When newer isn’t better: We’re paying too much for patented pharmaceuticals” which looks at the latest research from our President, Jon Karnon

    Read more →
    • 18 OCT 16
    • 0

    When newer isn’t better: We’re paying too much for patented pharmaceuticals.

    New pharmaceuticals are often listed on the Pharmaceutical Benefits Schedule at the same price as an equivalent pharmaceutical. Analysis of denosumab for the treatment of osteoporosis shows that the government has been paying almost $250,000 to gain the equivalent of one additional quality adjusted life year (QALY) since its comparator, alendronate went off patent. The Australian government should review listed pharmaceuticals as their comparator comes off patent to reflect the lower price of the comparator as well as any new clinical and economic data.

    Read more →
    • 04 OCT 16
    • 0

    HSRAANZ AGM and Call for nominations for the Executive Committee

    The Association is seeking nominations for its eight elected office bearers (President, Vice President, Secretary, Treasurer and four ordinary members). Office bearers are elected by and from among the members of the Association and hold office from the end of the Annual General Meeting immediately following their election is declared until the end of the second Annual General Meeting held thereafter. The results will be announced at our Annual General Meeting on 1 December.

    Read more →
    • 30 SEP 16
    • 0

    Watch the video from our latest webinar – Choosing Wisely – where we came from, where we are going and why we need you.

    In this webinar held on Sep 28, 2016 11:30 AM (AEST) Dr Robyn Lindner from NPS MedicineWise and Professor Adam Elshaug who is a member of the Choosing Wisely Advisory Group outlined the road travelled thus far in facilitating the roll out Choosing Wisely Australia: the challenges, successes and lessons learned. A video of the webinar is now available.

    Read more →

 

Skip to toolbar